Anavex Life Sciences Corp (AVXL)

[georgejjl]

Anavex 2-73 inventor

2007 Original Agreement, between Assignor (Vamvakides) and Assignee (Anavex) regarding ANAVEX 2-73 was amended in late 2012 in order to clarify language regarding IP ownership for Anavex of all IP. Also to be noted is that potential royalty to A Vamvakides is 6% is on net income - not net sales.

Dr. Vamvakides has spent 30 years in research focusing on the therapeutic/pharmacological areas of nootropes, anti-neurodegenerative (anti-Alzheimer), antiepileptic, antidepressive, and prototype molecules. During his career, Dr. Vamvakides has been published over 80 times in highly respected Medical/Scientific journals. In the past 30 years, Dr. Vamvakides has pioneered his expertise at the Institut National de la Sante et de la Recherche Medicale (INSERM) in Paris France, at the University of Athens (Greece) as well as at Chropi Pharmaceuticals (Piraeus, Greece), Ciba-Geigy (Basel, Switzerland) and Sanofi (Montpellier, France) for the development of new concepts in the aforementioned therapeutic/pharmacological areas.

Dr. Vamvakides holds a M.Sc. in Chemistry from Bordeaux University, France, a M.Sc. in Pharmacology, a M.Sc. in Biochemistry and a Ph.D. in Molecular Pharmacology all from the University of Paris, Medical School.

Good luck and GOD bless,